Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers have struck a truce after sparring over ...

She’d been injecting herself for years, and just gotten into trouble," says Dr. Kontis, explaining that the patient’s needle ...

The U.S. Food and Drug Administration has approved a self-injection version of Vyvgart Hytrulo (efgartigimod alfa and ...

Karen Coe claims she developed a blood clot after taking a GLP-1 for her diabetes and obesity SWNS A woman says she was prescribed a GLP-1 medication to treat her diabetes and obesity, but claims ...

FDA approved Vyvgart Hytrulo prefilled syringe for gMG and CIDP self-injection in 20–30 seconds. Human factor studies showed patients and caregivers safely administered the new formulation.

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa ...

The U.S. Food and Drug Administration (FDA) on Thursday approved a new option for patients to self-inject Argenx SE’s (NASDAQ:ARGX) Vyvgart Hytrulo with a prefilled syringe (efgartigimod alfa and ...

By Mariam Sunny and Kamal Choudhury (Reuters) -The U.S. Food and Drug Administration has approved a prefilled syringe version of Netherlands-based Argenx SE's blockbuster immune disorder drug, Vyvgart ...

Argenx’s VYVGART Hytrulo prefilled syringe for self-injection (efgartigimod alfa and hyaluronidase-qvfc) has received U.S. FDA approval for the treatment of adult patients with generalized myasthenia ...

The Amsterdam-based immunology company said the FDA approved a new option for patients to self-inject Vyvgart Hytrulo with a prefilled syringe for certain adult patients with generalized ...

VYVGART ® Hytrulo prefilled syringe for self-injection is approved as a 20-to-30-second subcutaneous injection administered by a patient, caregiver, or healthcare professional. Patients are able ...

SAN DIEGO, April 10, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) (Halozyme) today announced that argenx has received U.S. Food and Drug Administration (FDA) approval of VYVGART ® ...